APCR Issues Statement on COVID-19

Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies

Wed, 04/01/2020 - 12:43am

Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts...

      Related Stories 

Spring Shopping: Ping An Bets On Shionogi, TCMs In Coronavirus Aftermath

Wed, 04/01/2020 - 12:21am

China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.

      Related Stories 

Otsuka Dermatitis Candidate Looks Good At Phase III

Tue, 03/31/2020 - 8:51pm

New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.

      Related Stories 

Manipulating Metabolism: Lilly Links With UK Biotech Sitryx

Tue, 03/31/2020 - 9:26am

Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for...

      Related Stories 

Stockwatch: Repeating Past Mistakes At AbbVie

Tue, 03/31/2020 - 1:38am

AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and...

      Related Stories 

First Spring Sign: Chinese Vaccines Maker Gets $290m Funding

Tue, 03/31/2020 - 1:22am

With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment...

      Related Stories 

US Filing Eyed After Qurient's Novel TB Candidate Proves Mettle

Mon, 03/30/2020 - 4:39pm

South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and...

      Related Stories 

Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure

Mon, 03/30/2020 - 1:52pm

Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts...

      Related Stories 

Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

Mon, 03/30/2020 - 12:52pm

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a...

      Related Stories 

Sun Site Stares At FDA Action But Dent May Be Limited

Mon, 03/30/2020 - 8:25am

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug...

      Related Stories 

Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK

Mon, 03/30/2020 - 7:14am

The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier...

      Related Stories